Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 83, Issue 1, pp 161–167 | Cite as

A dose-escalation study of docetaxel, oxaliplatin, and S-1 (DOS) as a first-line therapy for patients with unresectable metastatic gastric cancer

  • Yasushi SatoEmail author
  • Tamotsu Sagawa
  • Hiroyuki Ohnuma
  • Masahiro Hirakawa
  • Yasuo Takahashi
  • Kyoko Hamaguchi
  • Koshi Fujikawa
  • Takayuki Nobuoka
  • Koichi Okamoto
  • Hiroshi Miyamoto
  • Naoki Muguruma
  • Ichiro Takemasa
  • Tetsuji Takayama
Original Article

Abstract

Purpose

The aim of this study was to determine the recommended dose (RD) for a docetaxel/oxaliplatin/S-1 (DOS) regimen in patients with unresectable gastric cancer and to preliminarily evaluate its efficacy.

Methods

Previously untreated patients with histologically proven unresectable metastatic gastric cancer were enrolled (n = 16). Docetaxel and oxaliplatin were administered intravenously on day 8 and S-1 was administered orally twice a day on days 1–14. Each cycle was repeated every 3 weeks. Dose-limiting toxicities (DLTs) were evaluated during the first treatment cycle. Three dose escalations of DOS were employed in this study: level 1 (50/100/80 mg/m2), level 2 (50/130/80 mg/m2), and level 3 (60/130/80 mg/m2).

Results

According to the 3 + 3 dose-escalating schedule, we determined that the RD and maximum tolerated dose for this regimen were level 1 and level 2, respectively. The DLTs were grade 3 diarrhea and febrile neutropenia. The overall response rate was 78% (7/9) for patients with measurable lesions and consisted of two complete responses and five partial responses. Five patients underwent conversion surgery. The median follow-up time was 19 months with median survival time and progression-free survival being 19.6 months and 7.6 months, respectively.

Conclusions

The results from this study demonstrated the safety and tolerability of DOS in unresectable metastatic gastric cancer patients and revealed promising preliminary efficacy with a high conversion rate. A phase II trial of DOS regimen using the identified RD is ongoing.

Keywords

Gastric cancer S-1 Docetaxel Oxaliplatin Phase I Conversion therapy 

Notes

Compliance with ethical standards

Conflict of interest

The authors have no conflicts of interest to declare.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Human and animal rights

This article does not contain any studies with animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Ferlay J, Soerjomataram I, Dikshit R et al (2014) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386CrossRefGoogle Scholar
  2. 2.
    Saka M, Morita S, Fukagawa T, Katai H (2011) Present and future status of gastric cancer surgery. Jpn J Clin Oncol 41:307–313CrossRefGoogle Scholar
  3. 3.
    Shah MA (2015) Update on metastatic gastric and esophageal cancers. J Clin Oncol 33:1760–1769CrossRefGoogle Scholar
  4. 4.
    Ohtsu A (2008) Chemotherapy for metastatic gastric cancer: past, present, and future. J Gastroenterol 43:256–264CrossRefGoogle Scholar
  5. 5.
    Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991–4997CrossRefGoogle Scholar
  6. 6.
    Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36–46CrossRefGoogle Scholar
  7. 7.
    Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215–221CrossRefGoogle Scholar
  8. 8.
    Yamada Y, Higuchi K, Nishikawa K et al (2015) Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol 26:141–148CrossRefGoogle Scholar
  9. 9.
    Bang Y-J, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positiveadvanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697CrossRefGoogle Scholar
  10. 10.
    Sato Y, Ohnuma H, Nobuoka T et al (2017) Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study. Gastric Cancer 20:517–526CrossRefGoogle Scholar
  11. 11.
    Fukuchi M, Ishiguro T, Ogata K et al (2015) Prognostic role of conversion surgery for unresectable gastric cancer. Ann Surg Oncol 22:3618–3624CrossRefGoogle Scholar
  12. 12.
    Yoshida K, Yamaguchi K, Okumura N et al (2015) Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer 19:329–338CrossRefGoogle Scholar
  13. 13.
    Takayama T, Sato Y, Sagawa T et al (2007) Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. Br J Cancer 97:851–856CrossRefGoogle Scholar
  14. 14.
    Sato Y, Takayama T, Sagawa T et al (2009) Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. Cancer Chemother Pharmacol 66:721–728CrossRefGoogle Scholar
  15. 15.
    Ohnuma H, Sato Y, Hirakawa M et al (2018) Docetaxel, cisplatin and S-1 (DCS) combination chemotherapy for gastric cancer patients with peritoneal metastasis: a retrospective study. Cancer Chemother Pharmacol 81:539–548CrossRefGoogle Scholar
  16. 16.
    Uemura N, Kikuchi S, Sato Y et al (2017) A phase II study of modified docetaxel, cisplatin, and S-1 (mDCS) chemotherapy for unresectable advanced gastric cancer. Cancer Chemother Pharmacol 80:707–713CrossRefGoogle Scholar
  17. 17.
    Mitsui Y, Sato Y, Miyamoto H et al (2015) Trastuzumab in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: feasibility and preliminary efficacy. Cancer Chemother Pharmacol 76:375–382CrossRefGoogle Scholar
  18. 18.
    Hirakawa M, Sato Y, Ohnuma H et al (2013) A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker. Cancer Chemother Pharmacol 71:789–797CrossRefGoogle Scholar
  19. 19.
    Association JGC (2011) Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 14:101–112CrossRefGoogle Scholar
  20. 20.
    Koizumi W, Nakayama N, Tanabe S et al (2011) A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601). Cancer Chemother Pharmacol 69:407–413CrossRefGoogle Scholar
  21. 21.
    Yamada Y, Boku N, Mizusawa J et al (2018) Phase III study comparing triplet chemotherapy with S-1 and cisplatin plus docetaxel versus doublet chemotherapy with S-1 and cisplatin for advanced gastric cancer (JCOG1013). J Clin Oncol 36(15_suppl):4009–4009CrossRefGoogle Scholar
  22. 22.
    Kim HS, Ryu M-H, Zang DY et al (2015) Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer. Gastric Cancer 19:579–585CrossRefGoogle Scholar
  23. 23.
    Krishnan AV, Park SB (2014) Chemotherapy-induced peripheral neuropathy: the end of the beginning? J Neurol Neurosurg Psychiatry 85:359–359CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Yasushi Sato
    • 1
    Email author
  • Tamotsu Sagawa
    • 2
  • Hiroyuki Ohnuma
    • 3
  • Masahiro Hirakawa
    • 3
  • Yasuo Takahashi
    • 2
  • Kyoko Hamaguchi
    • 2
  • Koshi Fujikawa
    • 2
  • Takayuki Nobuoka
    • 5
  • Koichi Okamoto
    • 4
  • Hiroshi Miyamoto
    • 4
  • Naoki Muguruma
    • 4
  • Ichiro Takemasa
    • 5
  • Tetsuji Takayama
    • 4
  1. 1.Department of Community Medicine for Gastroenterology and OncologyTokushima University Graduate School of Biomedical SciencesTokushimaJapan
  2. 2.Department of GastroenterologyHokkaido Cancer CenterHokkaidoJapan
  3. 3.Department of Medical OncologySapporo Medical University School of MedicineSapporoJapan
  4. 4.Department of Gastroenterology and OncologyTokushima University Graduate School of Biomedical SciencesTokushimaJapan
  5. 5.Department of Surgery, Surgical Oncology and ScienceSapporo Medical University School of MedicineSapporoJapan

Personalised recommendations